|Atossa Genetics, Inc.|
4105 East Madison Street
United States - Map
Atossa Genetics, Inc. operates as a healthcare company that focuses on the development and marketing of cellular and molecular diagnostic risk assessment products for breast cancer in the United States. Its diagnostic tests include the ForeCYTE Breast Health Test, which provides personalized information about the 10-year and lifetime risk of breast cancer for women between ages 18 and 65; and the ArgusCYTE Breast Health Test that offers information to help inform breast cancer treatment options and to help monitor potential recurrence. The company also intends to offers FullCYTE Breast Health Test, which is in development to assess the individual breast ducts for pre-cancerous changes in women; and NextCYTE Breast Cancer Test that is in the prevalidation phase to profile breast cancer specimens for prediction of treatment outcomes and distant recurrence in women newly diagnosed with breast cancer. Atossa Genetics, Inc. was founded in 2009 and is headquartered in Seattle, Washington.
|Dr. Steven C. Quay M.D., Ph.D., FCAP,
Chairman, Chief Exec. Officer, Pres and Treasurer
|Dr. Shu-Chih Chen Ph.D.,
Chief Scientific Officer and Director
|Mr. Kyle Guse Esq., CPA,
Chief Financial Officer, Principal Accounting Officer, Gen. Counsel and Sec.
|Mr. Christopher Destro ,
VP of Sales and Marketing
|Amounts are as of Dec 30, 2012 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|